A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma

Patients with relapsed or refractory lymphoma have limited treatment options, requiring newer regimens. In this Phase 1/2 study (NCT03769181), we assessed the safety, efficacy, and pharmacokinetics of isatuximab (Isa, anti‐CD38 antibody) in combination with cemiplimab (Cemi, anti‐programmed death‐1...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlo‐Stella, Carmelo, Zinzani, Pier Luigi, Sureda, Anna, Araújo, Luis, Casasnovas, Olivier, Carpio, Cecilia, Yeh, Su‐Peng, Bouabdallah, Krimo, Cartron, Guillaume, Kim, Won Seog, Cordoba, Raul, Koh, Youngil, Re, Alessandro, Alves, Daniela, Chamuleau, Martine, Le Gouill, Steven, López‐Guillermo, Armando, Moreira, Ilídia, van der Poel, Marjolein W. M., Abbadessa, Giovanni, Meng, Robin, Ji, Ran, Lépine, Lucie, Saleem, Rao, Ribrag, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092787/
https://www.ncbi.nlm.nih.gov/pubmed/36251503
http://dx.doi.org/10.1002/hon.3089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092787/
https://www.ncbi.nlm.nih.gov/pubmed/36251503
http://dx.doi.org/10.1002/hon.3089

Ejemplares similares